Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses
| Autor: | Kati Donner, Steven M. Stirdivant, Robert P. Mohney, Frej Fyhrquist, Antti-Pekka Sarin, Annukka M. Tuiskula, Jenni M. Rimpela, Kimmo Kontula, Timo P. Hiltunen |
|---|---|
| Přispěvatelé: | Clinicum, Kimmo Kontula Research Group, Department of Medicine, Institute for Molecular Medicine Finland, HUS Internal Medicine and Rehabilitation |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty medicine.drug_class education Single-nucleotide polymorphism Blood Pressure Pharmacology Polymorphism Single Nucleotide Amidohydrolases 03 medical and health sciences Double-Blind Method Predictive Value of Tests Internal medicine Genetics medicine Humans Prospective Studies Antihypertensive drug Antihypertensive Agents Finland Aged Aged 80 and over Angiotensin Receptor Antagonists Cross-Over Studies business.industry Genetic Variation Membrane Proteins Middle Aged Atenolol 3. Good health 030104 developmental biology Endocrinology Blood pressure Losartan Treatment Outcome Bisoprolol 317 Pharmacy Pharmacogenomics Molecular Medicine business circulatory and respiratory physiology medicine.drug |
| Zdroj: | Pharmacogenomics. 18(5) |
| ISSN: | 1744-8042 |
| Popis: | Aim: To replicate the genome-wide associations of the antihypertensive effects of bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study. Patients & methods: We analyzed association of four SNPs with atenolol and three SNPs with losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan). Results: rs2514036, a variation at a transcription start site of ACY3, was associated with blood pressure response to atenolol in men in LIFE. Response to bisoprolol was correlated to baseline plasma levels of N-acetylphenylalanine and phenylalanine (ACY3 substrate and end product, respectively) in GENRES study. NPHS1 variation rs3814995 was associated with losartan effect in LIFE. Conclusion: We provide support for two pharmacogenomic markers for beta-blockers and angiotensin receptor antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|